Role of ascorbic acid infusion in critically ill patients with transfusion‐related acute lung injury

Introduction In critically ill patients, transfusion‐related acute lung injury (TRALI) remains the leading cause of transfusion‐related fatalities in critical care settings and is associated with inflammation and oxidative stress state. Recent research raised the potential efficacy of high‐dose intr...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2022-05, Vol.88 (5), p.2327-2339
Main Authors: Kassem, Amira B., Ahmed, Islam, Omran, Gamal, Megahed, Mohamed, Habib, Tamer
Format: Article
Language:English
Subjects:
ascorbic acid
Ascorbic Acid - adverse effects
C-Reactive Protein
critical care
Critical Illness - therapy
Humans
inflammation
Interleukin-10
lung injury
Malondialdehyde
oxidative stress
Superoxide Dismutase
TRALI
Transfusion-Related Acute Lung Injury
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction In critically ill patients, transfusion‐related acute lung injury (TRALI) remains the leading cause of transfusion‐related fatalities in critical care settings and is associated with inflammation and oxidative stress state. Recent research raised the potential efficacy of high‐dose intravenous ascorbic acid (VC) in critically ill patients. Objective The aim of this trial was to investigate the effect of high‐dose intravenous VC as a targeted therapy for TRALI in terms of serum proinflammatory (interleukin [IL]‐8, IL‐1β, C‐reactive protein), anti‐inflammatory (IL‐10), oxidative stress (superoxide dismutase, malondialdehyde) markers, and plasma VC levels. Secondary outcomes were oxygenation (PaO2/FiO2 ratio), vasopressor use, duration of mechanical ventilation, ICU length of stay, 7‐day mortality and 28‐day mortality. Methods Eighty critically ill patients with TRALI (n = 80) were randomized to receive 2.5 g/6 h intravenous vitamin C for 96 hours (ASTRALI group) or placebo. Patients were followed up to measure the outcomes initially (T0) and at the end of treatment (T96). Results When compared to the control group, the ASTRALI group at T96 showed significantly higher median of IL‐10 (31.6 ± 25.8 vs 17.7 ± 12.0 pg/mL, P 
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15167